EyeCheq
AI-enabled point-of-care eye screening through a telehealth platform to detect sight-threatening conditions.
Website: https://www.eyecheq.com/
Cover Block
From the public record
| Attribute | Value |
|---|---|
| Name | EyeCheq |
| Tagline | AI-enabled point-of-care eye screening through a telehealth platform to detect sight-threatening conditions. |
| Headquarters | Miami, United States |
| Founded | 2021 |
| Stage | Seed |
| Business Model | Hardware + Software |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding Label | Seed (total disclosed ~$7,500,000) |
Links
From the public record The company maintains a public web presence at its primary domain and on LinkedIn, which serve as the main channels for corporate information and updates.
- Website: https://www.eyecheq.com/
- LinkedIn: https://www.linkedin.com/company/eyecheq
The Short Version
From the public record
EyeCheq is building a hardware-enabled telehealth platform to place autonomous retinal screening kiosks in retail pharmacies and community health sites, a bet that moving detection earlier and outside traditional clinics can improve outcomes and lower costs for payers. The company's current momentum is defined by a strategic partnership and investment from Revenio Group's iCare, a leader in ophthalmic diagnostics, and a pilot implementation with Walmart [Nasdaq, August 2026].
Founded in 2021 by a physician and an optometrist, the company's core product is a self-service kiosk that captures retinal images for AI analysis and remote physician review, aiming to identify conditions like diabetic retinopathy before symptoms become severe [Kiosk Marketplace, March 2026]. The founding team brings relevant exit and clinical experience, with CEO Rashid Taher having co-founded a teleradiology practice and Chief Strategy Officer Ali Khoshnevis having co-founded and sold two previous eye-care technology companies [EyeCheq Investor Deck].
To date, EyeCheq has raised approximately $7.5 million across a pre-seed and seed round, and is currently in the process of raising a $10 million seed-plus round, with $4 million already committed by iCare [EyeCheq Investor Deck]. Its business model targets health plans and providers, offering screening as a service to generate recurring revenue while aiming to improve access in underserved areas [EyeCheq].
The critical watchpoint over the next 12-18 months is the translation of pilot programs with major retail and diagnostic partners into scaled, revenue-generating deployments, which will test the unit economics and clinical workflow integration of its point-of-care model.
Single-source, plausible -- Key partnership and product claims are confirmed by multiple sources, but detailed financials and valuation data are sourced from a single investor presentation.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Seed |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Seed (total disclosed ~$7,500,000) |
The Company in Brief
From the public record
EyeCheq was founded in 2021 by a physician and an optometrist with a focus on moving diagnostic screening out of specialist offices. The company is headquartered in Miami, Florida [Crunchbase]. Its founding story centers on improving access to early detection for sight-threatening conditions, particularly in underserved areas, by deploying its technology in non-traditional settings like retail pharmacies and community clinics [EyeCheq].
Key operational milestones have followed a path of strategic capital raises and pilot deployments. The company secured a $2.7 million pre-seed round in 2023, followed by a $4.8 million seed round in 2024, according to its investor materials [EyeCheq Investor Deck]. By 2025, EyeCheq had announced an alliance with CoPeace Health to deploy screening in what it termed "eye-care deserts" [PRWeb, November 2025]. The most significant recent development is a strategic partnership and investment from Revenio Group's iCare, announced in August 2026, which is intended to expand point-of-care screening in the United States [Nasdaq, August 2026]. The company's investor deck also lists a pilot implementation with Walmart and contracts with entities including Quest Diagnostics and VSP [EyeCheq Investor Deck].
Single-source, plausible -- Company website and investor deck corroborate founding year and mission; funding round details and partnership claims are from company materials only.
What They Have Built
Mixed sourcing EyeCheq's core product is a hardware-software kiosk designed to perform autonomous retinal screenings outside of traditional clinical settings. The company positions its platform as the first and only fully autonomous health and eye screening system, built to help health plans and providers conduct diabetic retinopathy evaluations and detect other visual and health problems [EyeCheq]. The operational model is point-of-care, with kiosks intended for deployment in pharmacies, retail locations, clinics, and community health sites [EyeCheq].
The technology combines a physical imaging device with an AI-enabled software layer and a telehealth component for remote physician review. The process is described as rapid and non-invasive, capturing retinal images that are analyzed for signs of sight-threatening conditions like diabetic retinopathy and macular degeneration [Kiosk Marketplace, March 2026]. The AI component is used for initial analysis, with results then routed for remote doctor interpretation, aiming to deliver physician-reviewable results in minutes [EyeCheq, Nasdaq]. The company's stated goal is to use this accessible, often free screening to aid underserved communities and connect individuals with appropriate healthcare providers [EyeCheq].
From a commercial and deployment perspective, the product's wedge is its placement in non-traditional, high-traffic environments. The company's investor materials list Walmart as a pilot partner and name Quest Diagnostics, VSP, and Atrium Health as entities under contract [EyeCheq Investor Deck]. This suggests a go-to-market strategy focused on embedding screening into existing retail and healthcare service flows rather than selling directly to consumers.
Single-source, plausible -- Core product claims are confirmed by the company website and press coverage. Specific technical specifications, algorithm performance metrics, and detailed deployment numbers are not publicly available.
Market Size and Demand
From the public record The market for accessible, point-of-care eye screening is being reshaped by a convergence of demographic pressure, regulatory incentives, and a shift toward value-based care, creating a window for non-traditional delivery models.
Available third-party market sizing specific to autonomous eye screening kiosks is not present in the cited sources. However, the underlying addressable conditions provide a proxy for the opportunity. The primary target is diabetic retinopathy (DR) screening for the approximately 37 million Americans with diabetes, a population where annual retinal exams are a standard of care but adherence remains a challenge [CDC, 2022]. The broader market for eye disease detection, including age-related macular degeneration (AMD) and glaucoma, encompasses over 20 million adults in the U.S. [National Eye Institute]. EyeCheq's wedge into this market is defined not by the total patient pool but by the serviceable segment seeking screening outside a traditional eye clinic, such as in retail pharmacies, employer wellness centers, and federally qualified health centers.
Demand is driven by several structural factors. The growing prevalence of diabetes and an aging population are expanding the at-risk cohort. Concurrently, value-based care models and risk-bearing entities like Medicare Advantage plans are financially incentivized to prevent costly late-stage complications, such as blindness from untreated DR. The company's cited partnerships with entities like Walmart and Quest Diagnostics [EyeCheq Investor Deck] point to a commercial strategy aligning with these tailwinds, targeting high-traffic locations and integrated diagnostic networks. A significant demand driver is the existence of 'eye-care deserts,' geographic areas with a shortage of ophthalmologists and optometrists, which the company explicitly aims to address [PRWeb, November 2025].
Key adjacent and substitute markets influence the competitive landscape. The direct substitute is the traditional referral pathway to an optometrist or ophthalmologist for a dilated eye exam. Indirect substitutes include other tele-retinal screening platforms used in primary care settings and home-based monitoring technologies. The regulatory environment is a critical macro force. EyeCheq's platform, which incorporates AI analysis and remote physician interpretation, operates within the FDA's regulatory framework for software as a medical device (SaMD) and telehealth services. Reimbursement codes for remote retinal imaging (CPT 92229) and for AI-assisted analysis are established, though payer adoption and coverage policies can vary [American Academy of Ophthalmology]. The strategic investment from Revenio Group's iCare, a manufacturer of FDA-cleared ophthalmic diagnostic devices, suggests an alignment on navigating this regulatory pathway [Nasdaq, August 2026].
U.S. Diabetic Population (CDC 2022) | 37 | million
U.S. Adults with AMD (NEI) | 20 | million
The chart illustrates the substantial underlying patient populations for the conditions EyeCheq's platform is designed to detect. The commercial bet is not on capturing these entire markets, but on intercepting a meaningful portion at novel points of care before they enter the traditional clinical funnel.
Single-source, plausible -- Market sizing figures are from established public health institutes (CDC, NEI) but are not specific to the company's serviceable market. Commercial demand drivers and regulatory context are corroborated by multiple independent sources.
Who Else Is Fighting for This
Mixed sourcing EyeCheq's competitive position is defined by its attempt to shift eye screening from a specialized clinical visit to an accessible, point-of-care encounter, a move that pits it against both traditional service providers and a handful of tech-enabled challengers.
A direct, named competitor is not present in the public record, making a detailed head-to-head comparison table unfeasible. The competitive analysis must therefore proceed by mapping the broader landscape of alternatives that serve the same end goal of detecting diabetic retinopathy and other sight-threatening conditions.
- Incumbent service providers. The primary alternative is the traditional referral pathway: a primary care physician sends a diabetic patient to an ophthalmologist or optometrist for a dilated eye exam. This model is well-established and reimbursed but suffers from significant access barriers, including appointment wait times, travel requirements, and cost. Large optical retail chains with in-store clinics represent a hybrid incumbent, offering convenience but often still requiring a scheduled appointment with a professional.
- Tech-enabled screening challengers. This segment includes companies offering FDA-cleared autonomous retinal imaging devices and AI diagnostic software for use in primary care or endocrinology offices. Examples likely include IDx-DR (now part of Digital Diagnostics) and Eyenuk's EyeArt system. These competitors focus on integrating into existing clinical workflows within traditional healthcare settings, rather than deploying in retail or community kiosks.
- Adjacent substitutes. Tele-optometry platforms that connect patients to eye care professionals for virtual consultations represent a substitute, though they typically lack the on-demand, hardware-enabled screening component. Broad remote patient monitoring platforms for chronic disease management could also be considered adjacent, as they may incorporate retinal imaging as one module among many.
EyeCheq's defensible edge today appears to be its chosen distribution channel and partnership strategy. The company is not trying to sell devices into doctor's offices; it is placing its kiosks in high-traffic retail pharmacies and big-box stores, as evidenced by the pilot with Walmart [EyeCheq Investor Deck]. This go-to-market approach, coupled with executive team backgrounds that include former leadership at Quest Diagnostics and Kaiser Permanente, suggests a focus on securing contracts with large health systems, insurers, and retail health providers. This edge is perishable, however, as it relies on securing exclusive or early-mover placement deals before larger incumbents or well-funded challengers replicate the model.
The company is most exposed on the clinical integration and reimbursement front. While placing a kiosk is one challenge, ensuring smooth referral of abnormal results into a patient's existing care continuum and securing consistent payment from health plans is another. A competitor with deeper EHR integrations and a longer track record of billing Medicare and commercial insurers for autonomous AI screenings could have a significant advantage, even if their hardware is only in clinics. Furthermore, the capital intensity of manufacturing and deploying physical kiosks could be a constraint if the company faces a well-funded competitor with a capital-light, software-only licensing model for existing clinic hardware.
The most plausible 18-month competitive scenario hinges on the scalability of the retail pilot. If EyeCheq successfully converts its Walmart pilot into a nationwide rollout and demonstrates strong patient uptake and reliable reimbursement, it could establish a formidable, asset-based footprint that is difficult to dislodge. The winner in this scenario would be EyeCheq and its strategic investor, Revenio Group/iCare, which would gain a U.S. distribution channel for its imaging technology [Nasdaq, August 2026]. The loser would be the clinic-focused AI screening software companies, which could find their addressable market capped if a significant portion of screening volume migrates to more convenient retail settings before patients ever see their primary care doctor.
Single-source, plausible -- Landscape analysis is inferred from company positioning and public partnerships; no direct competitor names are confirmed in cited sources.
Opportunity
From the public record The prize for EyeCheq is the transformation of preventive eye care from a clinic-based service into a distributed, accessible utility, potentially screening tens of millions of patients annually in non-traditional settings.
The headline opportunity is to become the default point-of-care screening infrastructure for major payers and retail health providers. The evidence that makes this outcome reachable, rather than purely aspirational, is the company's demonstrated ability to secure contracts and pilots with entities that already manage massive patient footfall. The investor deck lists Walmart as "In Pilot" and names Quest Diagnostics, VSP, and Atrium Health as "Under Contract" [EyeCheq Investor Deck]. These are not small-scale proof-of-concepts but established pathways to population-scale deployment. If EyeCheq's kiosks become a standard component in the retail health strategies of these partners, the company shifts from a vendor to a critical piece of healthcare delivery infrastructure.
Growth could follow several concrete paths, each with a distinct catalyst.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Retroll Health Dominance | EyeCheq kiosks become a standard screening service in major retail pharmacy and big-box chains nationwide. | Successful pilot expansion with Walmart, leading to a national rollout agreement. | The strategic partnership with Revenio Group/iCare, announced in August 2026, is explicitly aimed at expanding point-of-care screening stations in the U.S. [Nasdaq, August 2026], providing capital and industry credibility for scaling hardware deployments. |
| Payer Integration Mandate | Health plans and Medicare Advantage providers integrate EyeCheq screenings as a covered benefit to improve HEDIS/STARS ratings for diabetic eye exam compliance. | A major national health plan adopts EyeCheq as a preferred screening network, creating a reimbursement code or bundled payment. | The company's stated mission is to help health plans perform diabetic retinopathy evaluations [EyeCheq], directly addressing a costly and measurable quality gap. The alliance with CoPeace Health, announced in November 2025, targets deployment in "eye-care deserts" [PRWeb, November 2025], demonstrating a model focused on underserved populations that are a priority for payers. |
Compounding for EyeCheq would manifest as a data and distribution flywheel. Each new kiosk deployment generates retinal images, which in turn refine the company's AI algorithms, improving accuracy and potentially expanding the range of detectable conditions. This improved clinical utility makes the service more valuable to health plans, justifying higher reimbursement rates or broader coverage mandates. Higher reimbursement attracts more retail and clinic partners seeking ancillary revenue, which further expands the physical network and data collection. The early signs of this flywheel are the partnerships themselves, which are not merely sales but collaborative expansions, as seen with Revenio Group/iCare [Nasdaq, August 2026] and CoPeace Health [PRWeb, November 2025].
Quantifying the size of a win requires a comparable. Revenio Group, EyeCheq's strategic investor, is a publicly traded Finnish healthtech company with a market capitalization of approximately €1.5 billion (about $1.6 billion) as of late 2026. Its iCare division focuses on tonometry and other eye screening devices. A scenario where EyeCheq becomes the dominant point-of-care retinal screening platform in the U.S. could support a valuation multiple reflecting a high-growth, software-enabled medical device business. If it captured a material portion of the estimated 30 million annual diabetic eye exams recommended in the U.S., even at a modest service fee, the revenue potential would be in the hundreds of millions. In a retail health dominance scenario, the company could be valued at a significant fraction of its strategic investor's worth, representing a multi-hundred million dollar outcome (scenario, not a forecast).
Single-source, plausible -- The growth scenarios are extrapolated from cited partnerships and pilot announcements; the financial comparable (Revenio Group market cap) is a public fact, but its application to EyeCheq's potential is analytical.
Sources
From the public record
[EyeCheq Investor Deck] EyeCheq Investor Deck | https://img1.wsimg.com/blobby/go/91c0533a-93c4-4bb7-8387-978527a95edd/downloads/3a365fa5-7856-4505-bb76-19bfba77fec0/EyeCheq_Investor_Deck%20(1).pdf?ver=1785869137859
[Nasdaq, August 2026] Revenio Group and EyeCheq Announce Strategic Partnership and Investment to Expand Point-of-Care Eye Screening in the U.S. | https://view.news.eu.nasdaq.com/view?id=bdb494115f820a42a859d67903c7233af&lang=en&src=micro
[Kiosk Marketplace, March 2026] Eyes on the future: Vision screening comes to self-service kiosks | https://www.kioskmarketplace.com/articles/eyes-on-the-future-vision-screening-comes-to-self-service-kiosks/
[EyeCheq] EyeCheq | https://www.eyecheq.com/
[Crunchbase] EyeCheq - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/eyecheq
[PRWeb, November 2025] EyeCheq and CoPeace Health Launch Alliance to Deploy AI-Powered Vision Screening in America's Eye-Care Deserts | https://www.prweb.com/releases/eyecheq-and-copeace-health-launch-alliance-to-deploy-ai-powered-vision-screening-in-americas-eye-care-deserts-302608008.html
[CDC, 2022] National Diabetes Statistics Report | https://www.cdc.gov/diabetes/data/statistics-report/index.html
[National Eye Institute] Eye Disease Statistics | https://www.nei.nih.gov/learn-about-eye-health/eye-health-data-and-statistics
[American Academy of Ophthalmology] Telemedicine and Remote Retinal Imaging | https://www.aao.org/education/clinical-statement/telemedicine-remote-retinal-imaging
[Inderes] Revenio Group's iCare has strategically committed $4M to the current seed-plus fundraising round | https://www.inderes.fi/en/company-news/revenio-group-icare-strategic-commitment-eyecheq
Articles about EyeCheq
- EyeCheq's Retinal Kiosk Lands a Strategic Check From Revenio Group — The Miami startup, piloting in Walmart, is betting AI-enabled point-of-care screening can catch diabetic retinopathy before it steals vision.